Sitagliptin CAS 486460-32-6 Purity >99.0% (HPLC) API Factory High Purity

Short Description:

Chemical Name: Sitagliptin

CAS: 486460-32-6

Purity: >99.0% (HPLC)

Appearance: White to Off-White Crystalline Powder

Sitagliptin for the treatment of type II diabetes mellitus

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Supply Sitagliptin Phosphate Monohydrate Related Intermediates:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate Intermediate CAS 486460-21-3

486460-32-6 - Chemical Properties:

Chemical Name	Sitagliptin
Synonyms	(3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
CAS Number	486460-32-6
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C16H15F6N5O
Molecular Weight	407.31
Melting Point	114.0~115.0℃
Density	1.61±0.10 g/cm3
COA & MSDS	Available
Place of Origin	Shanghai, China
Brand	Ruifu Chemical

486460-32-6 - Specifications:

Item	Specifications
Appearance	White to Off-White Crystalline Powder
Identification by HPLC	The Retention Time of Sample is Concordant With Reference Standard
Loss on Drying	<1.0%
Residue on Ignition	<0.20%
Related Substances
Any Single Impurity	<0.50%
Total Impurities	<1.0%
Purity	>99.0% (HPLC)
Enantiomeric Purity	<0.50%
Heavy Metals	<20ppm
Test Standard	Enterprise Standard
Usage	API; Type II Diabetes Mellitus

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

486460-32-6 - Application:

Sitagliptin (CAS: 486460-32-6), as a new type of antidiabetic drug, Sitagliptin Phosphate has the advantages of glucose dependence, moderate hypoglycemic effect, increased secretion without hypoglycemia, effectively alleviated hunger, and had no side effects such as nausea, vomiting, edema and increased body weight. Sitagliptin phosphate as a single drug treatment in patients with type II diabetes can significantly reduce the level of glycosylated hemoglobin (HbA1c). It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which can improve the human body's ability to reduce high blood glucose level. Sitagliptin was developed by Merck & Co. and approved for medical use in the United States in 2006.